Parkinson's disease is a common brain disorder in older adults that causes tremors (shaking), stiffness, and problems with movement. Among these symptoms, tremors-especially those that occur at rest-can be distressing and interfere with daily life. This study aims to compare two commonly used medications, propranolol and amantadine, to determine which one is more effective and safer in reducing tremors in people with Parkinson's disease.

This clinical trial was conducted with 220 adults aged 50 to 80 years who had a confirmed diagnosis of Parkinson's disease and noticeable resting tremors. Participants were randomly assigned to receive either propranolol or amantadine for 12 weeks, while continuing their usual Parkinson's medications. Tremor severity was measured using a standard scoring tool known as the Unified Parkinson's Disease Rating Scale (UPDRS). Quality of life and side effects were also closely monitored.

The hypothesis is that propranolol would be more effective in reducing tremor severity than amantadine, though it might be associated with more side effects. Both medications were given in tablet form, twice daily, and doses were adjusted based on patient response and tolerance.

At the end of the study, both groups showed improvement, but propranolol was more effective at reducing tremors. However, it caused more side effects such as tiredness and dizziness. Quality of life improved in both groups with no major difference between them. This study may help doctors decide which medication is more suitable for treating tremors in Parkinson's disease, based on the patient's health status and side effect tolerance.

Inclusion Criteria:

• UK Parkinson's Disease Society Brain Bank criteria [7] - Parkinson's Disease.
• Aged between 50 and 80 years.
• Significant (resting tremor score, defined as η ≥2 on the UPDRS Part III).
• At least 4 weeks prior to the study, a stable regimen of PD medication.

Exclusion Criteria:

• Severe bradycardia, history of asthma, or heart block (used instead of the propranolol group).
• History of seizures or significant renal impairment (Amantadine group).
• Cigarette smoking, pregnant or breastfeeding women.
• Patients with MMSE < 24.
• Participation in another clinical trial at the same time.